Inspire Pharmaceuticals’ dry eye treatment fails to meet late-stage study goals

Inspire dry eye treatment fails late-stage study

DURHAM, N.C. — Biotechnology company Inspire Pharmaceuticals Inc. said Thursday its drug candidate for dry eye disease failed to meet key treatment goals in a late-stage study.

The company said it is reviewing the late-stage, or Phase 3, clinical trial results for Prolacria.

The six-week study involved 490 patients, with the key goal of treating dry eyes.

Shares of Inspire slid in premarket trading to $5.29 from their Wednesday close of $6.61.